<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>0120-8748</journal-id>
<journal-title><![CDATA[Acta Neurológica Colombiana]]></journal-title>
<abbrev-journal-title><![CDATA[Acta Neurol Colomb.]]></abbrev-journal-title>
<issn>0120-8748</issn>
<publisher>
<publisher-name><![CDATA[Asociación Colombiana de Neurología]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S0120-87482019000200089</article-id>
<article-id pub-id-type="doi">10.22379/24224022238</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Reunión de expertos en epilepsia]]></article-title>
<article-title xml:lang="en"><![CDATA[Meeting of epilepsy experts]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Vergara Aguilar]]></surname>
<given-names><![CDATA[Jean Paul]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Nariño González]]></surname>
<given-names><![CDATA[Daniel]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Gómez Calzada]]></surname>
<given-names><![CDATA[Ubier Eduardo]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Gómez Arias]]></surname>
<given-names><![CDATA[Betty]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Martínez Micolta]]></surname>
<given-names><![CDATA[Paula]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Rosselli]]></surname>
<given-names><![CDATA[Diego]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Pantoja]]></surname>
<given-names><![CDATA[Camila]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Secretario de la Asociación Colombiana de Neurología  ]]></institution>
<addr-line><![CDATA[Bogotá ]]></addr-line>
<country>Colombia</country>
</aff>
<aff id="Af2">
<institution><![CDATA[,Pontificia Universidad Javeriana  ]]></institution>
<addr-line><![CDATA[Bogotá ]]></addr-line>
<country>Colombia</country>
</aff>
<aff id="Af3">
<institution><![CDATA[,Universidad de Antioquia  ]]></institution>
<addr-line><![CDATA[Medellín ]]></addr-line>
<country>Colombia</country>
</aff>
<aff id="Af4">
<institution><![CDATA[,Hospital San Vicente de Paúl  ]]></institution>
<addr-line><![CDATA[Medellín ]]></addr-line>
<country>Colombia</country>
</aff>
<aff id="Af5">
<institution><![CDATA[,Hospital Militar Central en Bogotá  ]]></institution>
<addr-line><![CDATA[Bogotá ]]></addr-line>
<country>Colombia</country>
</aff>
<aff id="Af6">
<institution><![CDATA[,Pontificia Universidad Javeriana  ]]></institution>
<addr-line><![CDATA[Bogotá ]]></addr-line>
<country>Colombia</country>
</aff>
<aff id="Af7">
<institution><![CDATA[,Pontificia Universidad Javeriana  ]]></institution>
<addr-line><![CDATA[Bogotá ]]></addr-line>
<country>Colombia</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>06</month>
<year>2019</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>06</month>
<year>2019</year>
</pub-date>
<volume>35</volume>
<numero>2</numero>
<fpage>89</fpage>
<lpage>98</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://www.scielo.org.co/scielo.php?script=sci_arttext&amp;pid=S0120-87482019000200089&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.co/scielo.php?script=sci_abstract&amp;pid=S0120-87482019000200089&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.co/scielo.php?script=sci_pdf&amp;pid=S0120-87482019000200089&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[RESUMEN Se estima que aproximadamente setenta millones de personas viven con epilepsia, de las cuales 80 % viven en países de ingreso bajo o medio como Colombia. Las personas con epilepsia viven con necesidades insatisfechas. Esta enfermedad, a pesar de ser prevalente, no se ve reflejada en las prioridades de los servicios de salud. Por lo anterior, existen importantes retos en el tratamiento integral de esta enfermedad. La epilepsia, enfermedad estigmatizada, más allá de los gastos farmacológicos tiene un impacto psicológico y social que resulta en un espectro de discapacidad muy variado, el cual cursa con dolencias notables como la depresión y la ansiedad. Asimismo, las personas con epilepsia tienen una menor tasa de empleo que las personas sin epilepsia, incluso ocho años después de haber comenzado la terapia farmacológica. El estado libre de crisis, uno de los objetivos principales en la terapia de epilepsia, es difícil de alcanzar en algunos pacientes y, si bien la cantidad de medicamentos anticonvulsivantes ha aumentado notablemente desde 1990, las crisis pueden ser generadas a partir de múltiples mecanismos, lo que se traduce en un reto a la hora de buscar blancos terapéuticos para los medicamentos ya que varias etiologías se pueden traducir clínicamente en tipos de crisis similares. Aunque la monoterapia sea el ideal del tratamiento en epilepsia, la prioridad es alcanzar una reducción en la frecuencia ictal o un estado libre de crisis, por lo que si no se alcanza con el primer medicamento, la opción de añadir un segundo medicamento es aceptada plenamente. Existe una gran preocupación alrededor del uso de los medicamentos genéricos, los copia o multifuente y los originales, ya que la concentración y la absorción son muy importantes para su eficacia y seguridad, y es conocido que no deben variar más del 5-10 % para evitar cambios del patrón ictal de los pacientes. Se ha considerado que el cambio a medicamentos genéricos o multifuente está asociado con cambios en perfil de seguridad y en el patrón ictal, además de un aumento del uso de los servicios de salud y una alta tasa de cambio a medicamentos de marca, lo que podría aumentar los costos en salud. Por todo lo anterior, se considera que una atención óptima a los pacientes con epilepsia hace referencia a un manejo interdisciplinario en el cual se garantice el acceso y el seguimiento, para lo cual se deben aceptar retos como el entrenamiento del personal en atención primaria y la continuidad del manejo para evitar cambios en la biodisponibilidad, el perfil de seguridad y la toxicidad de los medicamentos.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[SUMMARY It is estimated that approximately 70 million people live in the world with epilepsy, of which 80 °% live in low-or middle-income countries such as Colombia. Despite this, people with epilepsy live with unmet needs as, eventhough epilepsy is a prevalent disease, it is not reflected in the priorities of health services. This is why there are important challenges in the comprehensive treatment of epilepsy. Epilepsy is a stigmatized disease that, beyond pharmacological expenses, has a psychological and social impact that results in a very varied spectrum of disability, suffering from notable depressions such as depression and anxiety. Likewise, people with epilepsy have a lower employment rate than people without epilepsy even up to 8 years after starting pharmacological therapy. The crisis-free state, which is one of the main objectives in the therapy of epilepsy, is difficult to achieve in some patients and although the amount of anticonvulsant drugs has increased markedly since 1990, the crises can be generated from multiple mechanisms, which translates into a challenge when looking for therapeutic targets for medications since several etiologies can be translated clinically into similar types of crisis. Although monotherapy is the ideal treatment in epilepsy, the priority is to achieve a reduction in ictal frequency or a crisis-free state, so if it is not achieved with the first medication, the option of adding a second medication is fully accepted. . There is a great concern about the use of generic drugs, copy or multi-source and originals since the concentration and absorption is very important for their effectiveness and safety and it is known that they should not vary more than 5-10 % to avoid Changes in the ictal pattern of patients. It has been considered that the change to generic or multi-source drugs is associated with changes in the safety profile and changes in the ictal pattern, in addition to an increase in the use of health services and a high rate of change to brand-name drugs, which could increase health costs. For all of the above, it is considered that optimal care for patients with epilepsy refers to an interdisciplinary management in which access and follow-up are guaranteed, for which challenges such as training of personnel in primary care and health care should be accepted. continuity of management to avoid changes in bioavaila-bility, safety profile and drug toxicity.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[Epilepsia]]></kwd>
<kwd lng="es"><![CDATA[Medicamentos]]></kwd>
<kwd lng="es"><![CDATA[Calidad de vida (DeCS)]]></kwd>
<kwd lng="en"><![CDATA[Epilepsy]]></kwd>
<kwd lng="en"><![CDATA[Medications]]></kwd>
<kwd lng="en"><![CDATA[Quality of life (MeSH)]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kwan]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Brodie]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Early identification of refractory epilepsy]]></article-title>
<source><![CDATA[Natl Compr Cancer Netw]]></source>
<year>2000</year>
<volume>342</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>314-9</page-range></nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="">
<collab>World Health Organization</collab>
<source><![CDATA[Epilepsy key facts]]></source>
<year></year>
</nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Allers]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Essue]]></surname>
<given-names><![CDATA[BM]]></given-names>
</name>
<name>
<surname><![CDATA[Hackett]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Muhunthan]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Anderson]]></surname>
<given-names><![CDATA[CS]]></given-names>
</name>
<name>
<surname><![CDATA[Picles]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The economic impact of epilepsy: a systematic review]]></article-title>
<source><![CDATA[BMC Neurol]]></source>
<year>2015</year>
<volume>15</volume>
<numero>245</numero>
<issue>245</issue>
<page-range>16</page-range></nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="journal">
<collab>AMCP Managed Care &amp; Specialty Pharmacy Annual Meeting 2018</collab>
<article-title xml:lang=""><![CDATA[Meeting Abstracts]]></article-title>
<source><![CDATA[J Manag Care Spec Pharm]]></source>
<year>2018</year>
<volume>24</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>S1-116</page-range></nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Brodie]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Tolerability and safety of commonly used antiepileptic drugs in adolescents and adults: A clinician's overview]]></article-title>
<source><![CDATA[CNS Drugs]]></source>
<year>2017</year>
<volume>31</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>135-47</page-range></nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kehne]]></surname>
<given-names><![CDATA[JH]]></given-names>
</name>
<name>
<surname><![CDATA[Klein]]></surname>
<given-names><![CDATA[BD]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Raeissi S, Sharma S. The National Institute of Neurological Disorders and Stroke (NINDS) Epilepsy Therapy Screening Program (ETSP)]]></article-title>
<source><![CDATA[Neurochem Res]]></source>
<year>2017</year>
<volume>42</volume>
<numero>7</numero>
<issue>7</issue>
<page-range>1894-903</page-range></nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Duncan]]></surname>
<given-names><![CDATA[JS]]></given-names>
</name>
<name>
<surname><![CDATA[Sander]]></surname>
<given-names><![CDATA[JW]]></given-names>
</name>
<name>
<surname><![CDATA[Sisodiya]]></surname>
<given-names><![CDATA[SM]]></given-names>
</name>
<name>
<surname><![CDATA[Walker]]></surname>
<given-names><![CDATA[MC]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Adult epilepsy]]></article-title>
<source><![CDATA[Lancet]]></source>
<year>2006</year>
<volume>367</volume>
<numero>9516</numero>
<issue>9516</issue>
<page-range>1087-100</page-range></nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="">
<collab>Government Accountability Office</collab>
<source><![CDATA[Drug pricing: Research on savings from generic drug use (letter to Senator Orrin B. Hatch)]]></source>
<year>2012</year>
</nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Perucca]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The safety of generic substitution in epilepsy]]></article-title>
<source><![CDATA[Lancet Neurol]]></source>
<year>2016</year>
<volume>15</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>344-5</page-range></nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ngo]]></surname>
<given-names><![CDATA[SNT]]></given-names>
</name>
<name>
<surname><![CDATA[Stupans]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[McKinnon]]></surname>
<given-names><![CDATA[RA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Generic substitution in the treatment of epilepsy: Patient attitudes and perceptions]]></article-title>
<source><![CDATA[Epilepsy Behav]]></source>
<year>2013</year>
<volume>26</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>64-6</page-range></nlm-citation>
</ref>
<ref id="B11">
<label>11</label><nlm-citation citation-type="">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hills]]></surname>
<given-names><![CDATA[MD]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The psychological and social impact of epilepsy]]></article-title>
<source><![CDATA[]]></source>
<year>2007</year>
<volume>12</volume>
<numero>^sNeurol Asia</numero>
<issue>^sNeurol Asia</issue>
<supplement>Neurol Asia</supplement>
<page-range>10-2</page-range></nlm-citation>
</ref>
<ref id="B12">
<label>12</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Romero-Osorio]]></surname>
<given-names><![CDATA[Ó]]></given-names>
</name>
<name>
<surname><![CDATA[Gil-Tamayo]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Nariño]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Rosselli]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Changes in sleep patterns after vagus nerve stimulation, deep brain stimulation or epilepsy surgery: Systematic review of the literature]]></article-title>
<source><![CDATA[Seizure]]></source>
<year>2018</year>
<volume>56</volume>
<numero>40</numero>
<issue>40</issue>
<page-range>4-8</page-range></nlm-citation>
</ref>
<ref id="B13">
<label>13</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Mula]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Sander]]></surname>
<given-names><![CDATA[JW]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Suicide and epilepsy: do antiepileptic drugs increase the risk?]]></article-title>
<source><![CDATA[Expert Opin Drug Saf]]></source>
<year>2015</year>
<volume>14</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>553-8</page-range></nlm-citation>
</ref>
<ref id="B14">
<label>14</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Yoon]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Frick]]></surname>
<given-names><![CDATA[KD]]></given-names>
</name>
<name>
<surname><![CDATA[Carr]]></surname>
<given-names><![CDATA[DA]]></given-names>
</name>
<name>
<surname><![CDATA[Austin]]></surname>
<given-names><![CDATA[JK]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Economic impact of epilepsy in the United States]]></article-title>
<source><![CDATA[Epilepsia]]></source>
<year>2009</year>
<volume>50</volume>
<numero>10</numero>
<issue>10</issue>
<page-range>2186-91</page-range></nlm-citation>
</ref>
<ref id="B15">
<label>15</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Jennum]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Gyllenborg]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Kjellberg]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The social and economic consequences of epilepsy: A controlled national study]]></article-title>
<source><![CDATA[Epilepsia]]></source>
<year>2011</year>
<volume>52</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>949-56</page-range></nlm-citation>
</ref>
<ref id="B16">
<label>16</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Mahendran]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Speechley]]></surname>
<given-names><![CDATA[KN]]></given-names>
</name>
<name>
<surname><![CDATA[Widjaja]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Systematic review of unmet healthcare needs in patients with epilepsy]]></article-title>
<source><![CDATA[Epilepsy Behav]]></source>
<year>2017</year>
<volume>75</volume>
<page-range>102-9</page-range></nlm-citation>
</ref>
<ref id="B17">
<label>17</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Micoulaud-Franchr]]></surname>
<given-names><![CDATA[JA]]></given-names>
</name>
<name>
<surname><![CDATA[Bartolomei]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Duncan]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[McGonigal]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Evaluating quality of life in epilepsy: The role of screening for adverse drug effects, depression, and anxiety]]></article-title>
<source><![CDATA[Epilepsy Behav]]></source>
<year>2017</year>
<volume>75</volume>
<page-range>18-24</page-range></nlm-citation>
</ref>
<ref id="B18">
<label>18</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Singh]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Kumar Pandey]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Quality of life in epilepsy]]></article-title>
<source><![CDATA[Int J Res Med Sci]]></source>
<year>2017</year>
<volume>5</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>452-5</page-range></nlm-citation>
</ref>
<ref id="B19">
<label>19</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Leone]]></surname>
<given-names><![CDATA[MA]]></given-names>
</name>
<name>
<surname><![CDATA[Beghi]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Righini]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Apolone]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Mosconi]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Epilepsy and quality of life in adults: A review of instruments]]></article-title>
<source><![CDATA[Epilepsy Res]]></source>
<year>2005</year>
<volume>66</volume>
<numero>1-3</numero>
<issue>1-3</issue>
<page-range>23-44</page-range></nlm-citation>
</ref>
<ref id="B20">
<label>20</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Thomann Rey]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Rull del Águila]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Protal Rossetti]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[de la Peña Álvarez]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Calidad de vida relacionada con la salud y trabajo en la epilepsia]]></article-title>
<source><![CDATA[Med Segur Trab]]></source>
<year>2016</year>
<volume>62</volume>
<numero>243</numero>
<issue>243</issue>
<page-range>157-74</page-range></nlm-citation>
</ref>
<ref id="B21">
<label>21</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Chung]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Liu]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Ivey]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Huang]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Chung]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Guo]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Quality of life in epilepsy (QOLIE): insights about epilepsy and support groups from people with epilepsy]]></article-title>
<source><![CDATA[Epilepsy Behav]]></source>
<year>2012</year>
<volume>24</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>256-63</page-range></nlm-citation>
</ref>
<ref id="B22">
<label>22</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Brodie]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Barry]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Bamagous]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Norrie]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Kwan]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Patterns of treatment response in newly diagnosed epilepsy]]></article-title>
<source><![CDATA[Neurology]]></source>
<year>2012</year>
<volume>78</volume>
<numero>20</numero>
<issue>20</issue>
<page-range>1548-54</page-range></nlm-citation>
</ref>
<ref id="B23">
<label>23</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Semah]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Thomas]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Coulbaut]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Derambure]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Early add-on treatment vs alternative monotherapy in patients with partial epilepsy]]></article-title>
<source><![CDATA[Epileptic Disord Int Epilepsy]]></source>
<year>2014</year>
<volume>16</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>165-74</page-range></nlm-citation>
</ref>
<ref id="B24">
<label>24</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Abou-Khalil]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Selecting rational drug combinations in epilepsy]]></article-title>
<source><![CDATA[CNS Drugs]]></source>
<year>2017</year>
<volume>31</volume>
<numero>10</numero>
<issue>10</issue>
<page-range>835-44</page-range></nlm-citation>
</ref>
<ref id="B25">
<label>25</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Méndez-Ayala]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Nariño]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Rosselli]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Burden of epilepsy in Colombia]]></article-title>
<source><![CDATA[Neuroepidemiology]]></source>
<year>2015</year>
<volume>44</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>144-8</page-range></nlm-citation>
</ref>
<ref id="B26">
<label>26</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Walteros-Acero]]></surname>
<given-names><![CDATA[DM]]></given-names>
</name>
</person-group>
<source><![CDATA[Informe final de evento cisticercosis. Avances en el conocimiento de la enfermedad]]></source>
<year>2009</year>
<publisher-loc><![CDATA[Bogotá ]]></publisher-loc>
<publisher-name><![CDATA[Instituto Nacional de Salud]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B27">
<label>27</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kotsopoulos IAW Evers]]></surname>
<given-names><![CDATA[SMAA]]></given-names>
</name>
<name>
<surname><![CDATA[Ament]]></surname>
<given-names><![CDATA[AJHA]]></given-names>
</name>
<name>
<surname><![CDATA[Kessels]]></surname>
<given-names><![CDATA[FGH]]></given-names>
</name>
<name>
<surname><![CDATA[De Krom]]></surname>
<given-names><![CDATA[MCTFM]]></given-names>
</name>
<name>
<surname><![CDATA[Twellaar]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The costs of epilepsy in three different populations of patients with epilepsy]]></article-title>
<source><![CDATA[Epilepsy Res]]></source>
<year>2003</year>
<volume>54</volume>
<numero>2-3</numero>
<issue>2-3</issue>
<page-range>131-40</page-range></nlm-citation>
</ref>
<ref id="B28">
<label>28</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Halpern]]></surname>
<given-names><![CDATA[MT]]></given-names>
</name>
<name>
<surname><![CDATA[Renaud]]></surname>
<given-names><![CDATA[JM]]></given-names>
</name>
<name>
<surname><![CDATA[Vickrey]]></surname>
<given-names><![CDATA[BG]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Impact of insurance status on access to care and out-of-pocket costs for U.S. individuals with epilepsy]]></article-title>
<source><![CDATA[Epilepsy Behav]]></source>
<year>2011</year>
<volume>22</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>483-9</page-range></nlm-citation>
</ref>
<ref id="B29">
<label>29</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Pato Pato]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Cebrián Pérez]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Cimas Hernando]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Lorenzo González]]></surname>
<given-names><![CDATA[JR]]></given-names>
</name>
<name>
<surname><![CDATA[Rodríguez Constenla]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Gude Sampedro]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Analysis of direct, indirect, and intangible costs of epilepsy]]></article-title>
<source><![CDATA[Neurologia]]></source>
<year>2013</year>
<volume>26</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>32-8</page-range></nlm-citation>
</ref>
<ref id="B30">
<label>30</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Strzelczyk]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Haag]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Reese]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Nickolay]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Oertel]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
<name>
<surname><![CDATA[Dodel]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Trends in resource utilization and prescription of anticonvulsants for patients with active epilepsy in Germany from 2003 to 2013 - A ten-year overview]]></article-title>
<source><![CDATA[Epilepsy Behav]]></source>
<year>2013</year>
<volume>27</volume>
<page-range>433-8</page-range></nlm-citation>
</ref>
<ref id="B31">
<label>31</label><nlm-citation citation-type="book">
<collab>Organización Mundial de la Salud (OMS)</collab>
<source><![CDATA[Comité de expertos de la OMS en especificaciones para las preparaciones farmacéuticas - 34 informe]]></source>
<year>2000</year>
<publisher-loc><![CDATA[Washington ]]></publisher-loc>
<publisher-name><![CDATA[OMS]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B32">
<label>32</label><nlm-citation citation-type="book">
<collab>World Health Organization (WHO)</collab>
<source><![CDATA[WHO expert committee on specifications for pharmaceutical preparations]]></source>
<year>2006</year>
<publisher-loc><![CDATA[Washington ]]></publisher-loc>
<publisher-name><![CDATA[WHO]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B33">
<label>33</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Mayer]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[May]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Altenmuller]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Sandmann]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Wolf]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Clinical problems with generic antiepileptic drugs: comparison of sustained-release formulations of carbamazepine]]></article-title>
<source><![CDATA[Clin Drig Invest]]></source>
<year>1999</year>
<volume>18</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>17-26</page-range></nlm-citation>
</ref>
<ref id="B34">
<label>34</label><nlm-citation citation-type="journal">
<collab>Food and Drug Administration (FDA)</collab>
<article-title xml:lang=""><![CDATA[Bioavailability and bioequivalence studies submitted in NDAs or INDs - General considerations]]></article-title>
<source><![CDATA[Food Drug Adm Guid Ind]]></source>
<year>2014</year>
<page-range>1-26</page-range></nlm-citation>
</ref>
<ref id="B35">
<label>35</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sánchez]]></surname>
<given-names><![CDATA[GE]]></given-names>
</name>
<name>
<surname><![CDATA[Jung]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Yepez]]></surname>
<given-names><![CDATA[ML]]></given-names>
</name>
<name>
<surname><![CDATA[Hernández-Abad]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Relevancia del polimorfismo en el área farmacéutica]]></article-title>
<source><![CDATA[Rev Mex Ciencias Farm]]></source>
<year>2007</year>
<volume>38</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>57-76</page-range></nlm-citation>
</ref>
<ref id="B36">
<label>36</label><nlm-citation citation-type="book">
<collab>House of Commons Health Committee</collab>
<source><![CDATA[The influence of the pharmaceutical industry: fourth report]]></source>
<year>2005</year>
<publisher-loc><![CDATA[Londres ]]></publisher-loc>
<publisher-name><![CDATA[Stationery Office Ltd]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B37">
<label>37</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Heaney]]></surname>
<given-names><![CDATA[DC]]></given-names>
</name>
<name>
<surname><![CDATA[Sander]]></surname>
<given-names><![CDATA[JW]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Antiepileptic drugs: generic versus branded treatments]]></article-title>
<source><![CDATA[Lancet Neurol]]></source>
<year>2007</year>
<volume>6</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>465-8</page-range></nlm-citation>
</ref>
<ref id="B38">
<label>38</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Nuwer]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Brown]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Dodson]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Generic substitutions for antiepileptic drugs]]></article-title>
<source><![CDATA[Neurology]]></source>
<year>1990</year>
<volume>40</volume>
<page-range>1647-51</page-range></nlm-citation>
</ref>
<ref id="B39">
<label>39</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Crawford]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Feely]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Guberman]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Kramer]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Are there potential problems with generic substitution of antiepileptic drugs: a review of issues]]></article-title>
<source><![CDATA[Seizure]]></source>
<year>2006</year>
<volume>15</volume>
<page-range>165-76</page-range></nlm-citation>
</ref>
<ref id="B40">
<label>40</label><nlm-citation citation-type="">
<collab>European Parliament and the Council of the European Union</collab>
<source><![CDATA[Community code relating to medicinal products for human use]]></source>
<year>2001</year>
</nlm-citation>
</ref>
<ref id="B41">
<label>41</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kramer]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Biraben]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Carreno]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Guekht]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[de Haan]]></surname>
<given-names><![CDATA[GJ]]></given-names>
</name>
<name>
<surname><![CDATA[Jedrzejczak]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Current approaches to the use of generic antiepileptic drugs]]></article-title>
<source><![CDATA[Epilepsy Behav]]></source>
<year>2007</year>
<volume>11</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>46-52</page-range></nlm-citation>
</ref>
<ref id="B42">
<label>42</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Jankovic]]></surname>
<given-names><![CDATA[SM]]></given-names>
</name>
<name>
<surname><![CDATA[Ignjatovic Ristic]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Is bioavailability altered in generic versus brand anticonvulsants?]]></article-title>
<source><![CDATA[Expert Opin Drug Metab Toxicol]]></source>
<year>2015</year>
<volume>11</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>329-32</page-range></nlm-citation>
</ref>
<ref id="B43">
<label>43</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sander]]></surname>
<given-names><![CDATA[JW]]></given-names>
</name>
<name>
<surname><![CDATA[Ryvlin]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Stefan]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Booth]]></surname>
<given-names><![CDATA[DR]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Generic substitution of antiepileptic drugs]]></article-title>
<source><![CDATA[Expert Rev Neurother]]></source>
<year>2010</year>
<volume>12</volume>
<page-range>1887-98</page-range></nlm-citation>
</ref>
<ref id="B44">
<label>44</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Davis]]></surname>
<given-names><![CDATA[KL]]></given-names>
</name>
<name>
<surname><![CDATA[Candrilli]]></surname>
<given-names><![CDATA[SD]]></given-names>
</name>
<name>
<surname><![CDATA[Edin]]></surname>
<given-names><![CDATA[HM]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Prevalence and cost of nonadherence with antiepileptic drugs in an adult managed care population]]></article-title>
<source><![CDATA[Epilepsia]]></source>
<year>2008</year>
<volume>49</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>446-54</page-range></nlm-citation>
</ref>
<ref id="B45">
<label>45</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Cramer]]></surname>
<given-names><![CDATA[JA]]></given-names>
</name>
<name>
<surname><![CDATA[Glassman]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Rienzi]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The relationship between poor medication compliance and seizures]]></article-title>
<source><![CDATA[Epilepsy Behav]]></source>
<year>2002</year>
<volume>3</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>338-42</page-range></nlm-citation>
</ref>
<ref id="B46">
<label>46</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Malek]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Heath]]></surname>
<given-names><![CDATA[CA]]></given-names>
</name>
<name>
<surname><![CDATA[Greene]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[A review of medication adherence in people with epilepsy]]></article-title>
<source><![CDATA[Acta Neurol Scand]]></source>
<year>2017</year>
<volume>135</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>507-15</page-range></nlm-citation>
</ref>
<ref id="B47">
<label>47</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Offord]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Lin]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Wong]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Mirski]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Baker]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Impact of oral anti- psychotic medication adherence on healthcare resource utilization among schizophrenia patients with Medicare coverage]]></article-title>
<source><![CDATA[Community Ment Heal J]]></source>
<year>2013</year>
<volume>49</volume>
<page-range>625-9</page-range></nlm-citation>
</ref>
<ref id="B48">
<label>48</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sperling]]></surname>
<given-names><![CDATA[MR]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Sudden unexplained death in epilepsy]]></article-title>
<source><![CDATA[Epilepsy Curr]]></source>
<year>2001</year>
<volume>1</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>21-3</page-range></nlm-citation>
</ref>
<ref id="B49">
<label>49</label><nlm-citation citation-type="">
<collab>Institute of Medicine (US) Committee on the Public Health Dimensions of the Epilepsies</collab>
<source><![CDATA[Epilepsy across the spectrum: Promoting health and understanding]]></source>
<year>2012</year>
</nlm-citation>
</ref>
</ref-list>
</back>
</article>
